sample advanced wound care market landscape proposal

0 CLIENT X -‐ Whitespace Ideation Study:

Mid Term Opportunities Within Wound Care -‐ Confidential

CLIENT X

Whitespace Ideation Study: Mid Term Opportunities Within Wound Care



DATE

Mr. X Y Position Advanced Wound Care CLIENT X Location Location United Kingdom

Dear Mr. Y,

Per our conversation, Harrison Hayes is pleased to present a research proposal that will focus on making specific recommendations for CLIENT X’s unmet needs and to identify unmet needs and new opportunities that would create value generation to support the Advanced Wound Management sector.

In this proposal, we present a review of the objectives, scope, qualitative research and ideation methodology of this project. We will also go into more detail regarding the ideation methodology that Harrison Hayes will utilize to obtain unique insights into identifying and assessing disruptive areas in Advanced Wound Management where there are proven unmet needs, including identification of current and future market trends, identification of technologies and products to be in-‐licensed or acquired, and make recommendations as to which of these technologies hold the greatest promise for adoption.

To complement our work on this project, Harrison Hayes will rely on a dynamic network of KILs (Key Innovation Leaders) who have deep domain expertise and are well respected in their specific disciplines. This assures that our research, ideation and points of view are of the highest value.

We welcome your suggestions and comments and look forward to a great working relationship.

Sincerely,

Bill Smith Managing Director Harrison Hayes, LLC Charlotte, NC



INTRODUCTION Modern wound care is a complex process supported worldwide by obtuse and heterogeneous funding and reimbursement systems. Wound care is an integral part of all areas of healthcare and all types of practice, and the patient population encompasses the spectrum from infants to the elderly. Wound care may involve acute wounds (e.g., trauma and surgical incisions) or chronic wounds (e.g., pressure ulcers, or vascular or diabetic ulcers).i Currently, chronic wound and ulcer management remains one of the most costly healthcare challenges. ii In the US alone, complex wounds affect more patients than heart attack and stroke combined, involving 5-‐7 million patients and over $20 billion in healthcare expenditures. These complex wounds result in approximately 150,000 amputations a year, with about 80,000 of these attributable to diabetes and peripheral arterial disease.iii It is estimated that, globally, biofilm infections alone are over 14 million, accounting for more than 350,000 deaths.iv

UK NHS Annual spending on different types of wounds. From: Tissue viability in tomorrow’s NHS. R White. Journal of Wound Care 17(3):97-‐99. Figure 3, p.99. March 2008.



The fundamental paradigm of moist wound healing, a passive approach utilizing dressings and technology to create the appropriate conditions for healing and then letting the wound heal itself, has not shifted significantly since its inception more than 40 years ago.v The longevity of this paradigm is in part because, in most cases, this model is successful. However, this success does not extend to the most challenging complex wounds, such as diabetic foot ulcers and those on limbs with critical limb ischemia. Notwithstanding the widespread incidence and complex nature of wounds and wound care, and the development of national, regional, and international guidelines, relatively few patients receive state-‐of-‐the-‐art or optimal wound care, even in developed countries.1 However there have been recent indications that this paradigm is beginning to shift as new molecular and genetic information regarding wound healing and scar development,vi,vii and microbiologic information regarding biofilm production and delayed healing, become available.4 Wounds from surgery and trauma are by far the most common types of wounds and, with millions of surgical procedures performed annually worldwide, the market for wound care products and technologies for surgical wounds alone is significant. Other major drivers for the wound care industry are aging of the population and advances in biotechnology are major drivers for the wound care industry. As the population ages there will continue to be increased demand for surgical interventions, and diabetic ulcers are expected to continue to form one of the largest sectors of this market. As healthcare lumbers slowly towards personalized medicine, there is also an increasing emphasis being made on personalization of wound care, a major shift from previous generic treatment methods. Increasingly, physicians are directly administering Advanced Wound Care Management products for the treatment of both chronic and acute wounds, leading to greater success in terms of wound healing. These factors, combined with a drive towards home healthcare in an effort to gain cost efficiencies while improving patient outcomes, acceptance and reimbursement from third-‐party payers, increasing professional expertise in administering advanced wound management products, improved cost effectiveness, and technological advances in the treatment of wounds, are all expected to drive the market over the next five years and beyond.viii



From: Worldwide Wound Management, 2009: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World. MedMarket Diligence. September 2009. The U.S. wound management market was valued at just under $5 billion in 2009, while the global market was valued at over $20 billion.ix The global demand for wound management is expected to increase 4.6% per year through 2013 to approximately $28.7 billion.x The market includes therapeutic support surfaces, static and dynamic compression therapy, moist, advanced, and interactive wound dressings, wound closure devices, hemostats, tissue sealants, and anti-‐adhesion. The internal tissue management sector comprised 40.8% of the overall market in the US in 2009, with expected growth in this sector to 49.2% by 2016 as the divide between external and internal healing diminishes. This change is attributable to the movement of companies traditionally involved in durable medical equipment and medical disposables to the biologic surgical markets.xi



Demand in developing countries is expected to expand at a faster rate than in developed countries, although approximately 75% of the total increase in the wound management market will be in developed countries due to advanced medical delivery systems and widespread insurance coverage of residents for primary care procedures.10 Wound closures will remain the largest segment of the wound management market, with world demand expanding 3.5 percent annually to $11.1 billion in 2013, although advances in minimally invasive technologies are expected to inhibit demand beyond this level. 10,xii Global demand for wound dressings is expected to increase 5.4 percent annually through 2013 reflecting the broad indications of this sector. In addition, infection control standards, which promote more frequent changes of wound dressings, in combination with increased utilization of biological and synthetic wound dressing materials, support favorable global projections for wound dressings.10 Advanced Wound Care Management in the form of emerging wound care products and technologies are well-‐positioned to capitalize on growth, with bioengineered growth factors and negative pressure devices showing the fastest gains in demand.10 Advanced Wound Care Management technologies mimic the body’s natural physiology and/or regenerative pathways and include tissue-‐engineered skin substitutes, synthetic and harvested regeneration matrices, autologous grafts and biologically active cellular therapies.xiii These technologies first emerged in 1999 as treatment for refractory wounds, and today there are a number of products currently available, with others in pre-‐clinical or clinical development. Recent developments include changes in synthetic dressing materials (e.g., hydrocolloid, hydrofibre, hydrogel, alginate, foam, and film); Negative Pressure Wound Therapy (NPWT); Antimicrobial Wound Dressings (e.g., silver-‐based dressings); and Advanced Therapies (tissue engineering such as xenogeneic tissue scaffold, bilayered human dermal substitutes, and use of embryonic stem cells; bio-‐interactive dressings; collagen-‐based dressings; and hyaluronic acid and growth factors).xiv In addition, surgical techniques such as endoscopic subfascial ligation of venous perforators, endovascular arterial repair techniques, have become important in surgical and trauma wounds.xv The Bioengineered and Advanced Wound Care Management market is experiencing continued growth, as aging of the population in developed countries leads to increasing numbers of chronic wounds due to conditions such as diabetes which are forecast to grow worldwide during the next fifteen years.2 Advanced Wound Care Management technologies and therapies currently in research/pre-‐



market/early market stage include: ultrasound wound cleaning, activated collagen, manuka honey, noncontact normothermic wound therapy, tissue-‐engineered skin substitutes and growth factors.14 French researchers have demonstrated a method of using human embryonic stem cells to create new skin that could help victims of serious burns by having readily available temporary skin with a low level of rejection.xvi Other recent studies indicating the ability of these technologies to facilitate healing in otherwise non-‐healing wounds and to improve patient outcomes places them on a competitive field in terms of total treatment costs despite their increased individual costs. It is expected that the number of indications for, and third party payer acceptance of, these next-‐generation Advanced Wound Care Management technologies will drive significant growth through 2015.2 In the Advanced Wound Care Management market segment, tissue-‐engineering products have a very small market share with $71.8 million in revenues in 2008, a growth rate of 11.6%, and a market share of 20.6% of overall revenues. Bio-‐interactive dressings generated the highest revenues in 2008, with 79.4% share of overall revenues. The tissue engineering segment accounted for 20.6 per cent of the overall revenues. Another significant area for expected future growth within the Bioengineered and Advanced Wound Care Management market is the development of biomarkers for healing, for differentiation between causes of non-‐healing, for determination of biofilm or differentiation between planktonic and biofilm phentoype bacteria, and for determination of susceptibility of wound to biomechanical stimulation of healing from technologies like NPWT. NPWT is also expected to show continued growth as the home healthcare equipment market continues to develop.8 The global NPWT market, with 2009 estimates at $640 million, is expected to show growth of 8.2% annually over the next seven years, reaching $1.1 billion by 2016. Drivers for this growth will primarily be an increasing incidence of chronic wounds, diabetes, and an aging population. Although the US remains the largest NPWT market valued at $380.6m in 2009, it is forecast to grow by 7.7% annually for the next seven years to reach $594.6m in 2016.xvii However, most of the demand through 2016 will be originating from EU economies, creating a shift in the center of global NPWT market activity. Italy, France and Germany are expected to show faster NPWT market growth than other market sectors, with an expectation to contribute 21% by 2016, driven by an increasingly diabetic population and improvements in diabetes and wound management.8,17



Europe currently appears to be the global leader in integrating advanced wound management therapies into the traditional therapy market.14 However the lack of standards and the lack of common organizations across EU member states have hindered market development, leading to the development of EU-‐wide organizations such as the Advanced Wound Care (AWCS) of Eucomed (European Medical Technology Industry Association). In addition, the move toward home health care acts as a market restraint until the healthcare systems better fund reimbursement for these treatments. Conversely, as EU healthcare systems continue a paradigm shift from traditional to high-‐tech treatment modalities, the cost-‐effectiveness of Advanced Wound Care Management therapies and technologies, including their ability to be used as part of home treatments, will increase in importance as a market driver. Consolidation of the market has increased the ability of companies to fund research and development, as well as overcome the regulatory hurdles of each of the EU members, allowing for more rapid introduction of new therapies. The UK, having wider acceptance of Advanced Wound Care Management technologies and therapies by the medical community, and reimbursement of all phases of treatment, has the highest revenue share of any EU market (approximately 28.2%), closely followed by Germany at 27.8%.14 Market penetration in the rest of the EU, where market share currently ranges from 17.8% in France to about 5-‐8% in the rest of the EU, is expected to increase by 2015.14 The EU market is currently more favorable towards equipment-‐based and other advanced therapy modalities than towards traditional advanced moist dressings for chronic wound healing.14



REFERENCES

i Eucomed Wound Care Policy Paper. September 23, 2009. ii Bioengineered Wound Care. Greystone Associates, Aug 2009. iii Researchers Develop Device To Predict Diabetic Wound Healing. Medical News Today. May 25, 2010. http://www.medicalnewstoday.com/articles/189788.php.

iv Chronic wounds and the medical biofilm paradigm. R.D. Wolcott, D.D. Rhoads, M.E. Bennett, B.M. Wolcott, L. Gogokhia, J.W. Costerton, S.E. Dowd. Journal Of Wound Care. 19(2):45-‐53. February 2010.

v A new vision for wound healing. Tom Pollard, Ed. Journal of Wound Care. 17(4):141 April 2008.

vi Lack of p21 expression links cell cycle control and appendage regeneration in mice. K Bedelbaevaa, A Snydera, D Gourevitcha, L Clarka, X-‐M Zhanga, J Leferovicha, JM Cheverudb, P Lieberman, E Heber-‐Katz. PNAS 107(13):5845-‐5850. March 30, 2010.

vii Epithelial to Mesenchymal Transition in Human Skin Wound Healing Is Induced by Tumor Necrosis Factor-‐ through Bone Morphogenic Protein-‐2. C Yan, WA Grimm, WL Garner, L Qin, T Travis, N Tan and Y-‐P Han. Am J Pathol. 176(5):2247-‐58. May 2010.

viii The Future of the US Advanced Wound Management Market to 2012. Aarkstore Enterprise. Mar 20, 2009.

ix U.S. Market for Wound and Tissue Management 2010. iData Research Inc. December 2009. World Wound Management Products (Industry forecasts for 2013 & 2018). The Freedonia Group. October 2010.

x World Wound Management Products (Industry forecasts for 2013 & 2018). The Freedonia Group. October 2010.

xi U.S. Market for Wound and Tissue Management 2010. iData Research Inc. December 2009.

xii Western European Wound Closure Market. Frost & Sullivan. May 20, 2009. xiii Bioengineered Wound Care. Greystone Associates, Aug 2009. xiv Western European Advanced Wound Management Market. Frost & Sullivan. January 2, 2009.

xv Wound Care Markets, 4th. Edition, Vol. III: Surgical and Trauma Wounds Apr 2009 Kalorama Information.

xvi Stem cells could create new skin to help burns victims. BBC News. November 20, 2009. http://news.bbc.co.uk/2/hi/8368976.stm

xvii Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016. GlobalData. December 2009.



SCOPE It is our understanding that CLIENT X would like Harrison Hayes to investigate the unmet needs and new product opportunities within mainstream Advanced Wound Care Management, with a particular but not exclusive focus on Europe for adjacencies that leverage CLIENT X’s current competencies in Advanced Wound Care Management over the Near-‐ to Mid-‐Term. Harrison Hayes will provide a thorough review of the future of the European and global Advanced Wound Care Management space, with identification and assessment of how best to leverage adjacencies of core competencies to take advantage of changing technologies and therapies within the Advanced Wound Care Management space and its adjacencies.

OBJECTIVES

• Identification and review of unmet needs and new product opportunities particularly, but not exclusively, in Europe that are within mainstream Advanced Wound Management and that would create value generation by looking out three to five years (Mid-‐Term).

• Identification of Advanced Wound Care Management emerging technologies and therapies, and companies to be in-‐licensed or acquired, with a focus on Europe, that will create value generation within three to five years (Mid-‐Term).

• Identification of strategies to facilitate and increase awareness of the potential return on investment of Advanced Wound Care Management emerging technologies and opportunities both in the future and when engaged with specific opportunities over the Mid-‐Term, with a particular focus on Europe.

• Identification of current and future trends in Advanced Wound Care Management adjacent business units particularly, but not exclusively, in Europe.



METHODOLOGY Harrison Hayes proposes to begin the project by meeting with CLIENT X’s project team to conduct due diligence and review currently available information. The purpose of this meeting is to verify the scope of the assignment, answer questions, and review the timeline. Harrison Hayes actively engages our clients in collaborative, interactive dialogue throughout the project. We suggest weekly meetings to review and assess the direction and progress of the project.

METHODOLOGY KOLs

The project will begin with a customized Key Opinion Leader Primary Qualitative Research Module designed specifically for CLIENT X. Key Opinion Leaders (“KOLs”) are recognized experts in the Advanced Wound Care Management industry. We will look to these KOLs to provide valuable insight into the best mechanisms for leveraging of adjacencies to core competencies in Advanced Wound Care Management particularly, but not exclusively, in Europe. The KOL questionnaire will be developed through a collaborative effort with CLIENT X in order to ensure that the focus of this project is being properly addressed. The questionnaire is to be used as a platform for exploration and discussion. All interviews will be conducted directly by Harrison Hayes’s Principals and Research Team who have the autonomy to probe deeper and maneuver through unique issues that arise during discussion with the KOLs – what we refer to as improvisational interviewing. Our Research Team is able to select the most appropriate questions to ask each KOL due to our extensive knowledge and involvement with the project’s goals. These interviews are conducted individually, which allows us to focus directly on the expertise that each KOL possesses. Improvisational interviewing yields valuable qualitative interview data unlike structured interview surveys. Instead of merely moving from question to question, our Research Team is able to adapt based on KOLs’ response to questions, thus obtaining additional insight.



METHODOLOGY Secondary Research

To complement our Primary Qualitative Key Opinion Leader research we will concurrently perform secondary research from syndicated, internal, and public sources. We believe secondary research will provide us with useful data regarding current and future trends in advanced wound care technology particularly, but not exclusively, in Europe. We will look to uncover macro trends impacting CLIENT X’s core competencies and future opportunities, with a focus on Mid-‐Term opportunities and trends. Our Secondary Research Methodology and its role in the project’s outcome are discussed in further detail below. Harrison Hayes believes that through the effective marrying of primary KOL insight and secondary research – along with our partnership with the CLIENT X project team – we can obtain uncommon insight into the potential to determine how best to leverage core competencies in Advanced Wound Care Management particularly, but not exclusively, in Europe. Our research module begins by concurrently identifying and recruiting a customized panel of Key Opinion Leaders (Tables 1 and 2) and developing a project specific Key Opinion Leader questionnaire (Table 3). Please note that the questions in Table 3 are examples and not all-‐inclusive of what we will ultimately ask.

METHODOLOGY KOLs

Table 1: Examples of Key Opinion Leaders (Note: Additional KOLs will emerge from Selected Representative Areas)

• Pharmacologists, Immunologists, Tissue Engineers, Nanotechnology and Nanomedicine Specialists, Biomaterials Specialists, Proteomic and Genomic Specialists, and Medical Device Specialists with a European and global focus

• Board of Directors for Advanced Wound Care Device Manufacturers with a European and global focus

• Physicians from Representative Institutions Published in Advanced Wound Care Technologies and Therapies with a European and global focus

• Academic Thought Leaders Involved/Published in Advanced Wound Care Technologies and Therapies with a European and global focus



• Academic Thought Leaders Involved/Published in Pharmacology, Immunology, Dermatology, Surgery, Orthopedics, Plastic Surgery, Nanotechnology, Nanomedicine, Proteomics, Genomics, Tissue Engineering, Biomaterials, and Medical Devices Relevant to Advanced Wound Care with a European and global focus

• Strategic Leaders in Advanced Wound Care Technologies and Therapies with a European and global focus

• Decision Makers for National Advanced Wound Care Technologies and Therapies Regulatory and Reimbursement Policy with a European and global focus

METHODOLOGY Potential KOLs

Table 2: Examples of Potential Key Opinion Leaders (Note: Additional KOLs will emerge from Selected Representative Areas)

Name Title / Expertise Organization / Location

Zena Moore, MSc, FFNMRCSI, PG Dip, Dip Management, RGN

President, Dept. of Nursing and Midwifery, European Wound Management Association. Lecturer in Wound Healing & Tissue Repair and Research Methodologies, Royal College of Surgeons in Ireland

Dept. of Nursing and Midwifery Royal College of Surgeons, Ireland Dublin, Ireland

Marco Romanelli, MD, PhD

Extensive clinical experience managing leg ulceration patients; responsible for Critical Wounds Clinic at University Hospital of Pisa; coordinated European Pressure Ulcers Prevalence Project; Immediate Past President, European Wound Management Association.

Dept. of Dermatology University of Pisa Pisa, Italy

Patricia Price, Ph.D., A.F.B.Ps.S.,

Chartered Health Psychologist / Director of the Wound Healing Research Unit in Cardiff at University of Wales College of Medicine; Honorary Secretary, European Wound Management Association

Director of the Wound Healing Research Unit Cardiff University of Wales College of Medicine Cardiff University Cardiff, UK

Sue Bale, Dr, FRCN, PhD, BA, RGN, NDN, RHV, PG Dip, Dip Nursing

Wound healing research expert spanning 21 years; 110 publications in peer-‐reviewed journals; 14 books & chapters; 62 international conference papers; 28 posters at international conferences, and 12 videos & CDs. Recorder, European Wound Management Association

Gwent Healthcare NHS Trust Torfaen, Wales




Peter Carmeliet

Research in Role of VEGF in angiogenesis in health and disease; Therapeutic antiangiogenesis with anti-‐PlGF; Therapeutic revascularization of ischemic tissues; Therapeutic hibernation of ischemic tissues; Endothelial normalization to prevent metastasis & promote therapeutic revascularization of ischemic tissues; VEGF therapy for neurodegeneration; Oxygen Sensors at the crossroads of metabolism & angiogenesis

Vesalius Research Centrum O&N I Herestraat 49 -‐ bus 00912 B-‐3000 Leuven

Bernard Coulomb, PhD

Wound healing, dermal skin substitute, research scientist; co-‐founder ScarCell Therapeutics; European Tissue Repair Society Board.

INSERM U532 Institut de Recherche sur la Peau Pavillon Bazin, Hôpital Saint-‐Louis, 1 avenue Claude Vellefaux 75475 Paris cedex 10, France

Finn Gottrup, MD, DM Sci

Leading global specialist on wound healing; more than 15 years’ experience with treatment of chronic wounds; key figure in establishment of the first two interdisciplinary wound healing centers in Denmark: University Hospital of Odense and Bispebjerg Hospital; Prof of Surgery.

University of Southern Denmark, University Center of Wound Healing, Department of Plastic and Reconstructive Surgery, Odense University Hospital, Denmark

Martin Koschnik

Since 2006 represents German Wound Healing Society (DGfW) in the EWMA;. DGfW made enormous efforts to develop and promote several evidence-‐based wound healing projects (evidence-‐based education curriculum for nurses and doctors & an evidenced-‐based guideline on topical treatment of chronic wounds in patients with severe risks).

Hospital/Clinic Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE Rua Professor Lima Basto Lisbon 1099-‐023 PORTUGAL

Jean-‐Jacques Lataillade

Stem Cells and Cell Therapy; CTSA representative to STEM-‐Pole; European Tissue Repair Society Board

Service de Santé des Armées (SSA) / Thérapie cellulaire des brûlures graves -‐ Hôpital Militaire Percy Clamart Unité de recherche : Hôpital d'instruction des armées Percy 101, avenue Henri Barbusse BP 406 92141 Clamart Cedex

Liliane Michalik

PhD in microtubule-‐associated proteins in the group of Jean-‐François Launay, INSERM; post-‐doctoral training in elucidating the roles of the nuclear hormone receptors PPARs in skin homeostasis and repair; research in skin repair, UV induced skin cancer, angiogenesis, peroxisome proliferator-‐activated receptors.

UNIL Genopode Building CH -‐ 1015 Lausanne, Switzerland

Filip Stillaert Assisting academic staff; flap-‐graft viability; tissue engineering.

Department of Plastic Surgery, Gent University Hospital, De Pintelaan 185, B-‐9000 Gent, Belgium.

Miikka Vikkula, MD, PhD

Professor of Human Genetics; genetics of vascular anomalies; mechanisms of altered angiogenesis.

Laboratory of Human Molecular Genetics de Duve Institute Université catholique de Louvain Avenue Hippocrate 74, BP 75.39, B-‐1200 Brussels, Belgium.




Sabine Werner, PhD

Research interests in molecular & cellular mechanisms of cutaneous wound repair & parallels to cancer; mechanisms underlying UV-‐induced skin damage; pathogenesis of inflammatory skin disease.

HPM, D 42 Schafmattstrasse 18 8093 Zurich SWITZERLAND

Keith Harding MB MRCGP FRCS

Trained in general surgery and in family medicine with longstanding interest in wound healing; Clinical Director of the Wound Healing Research Unit; Head of the Department of Surgery and Professor of Rehabilitation Medicine (Wound Healing); specializes in treating wound healing problems; has authored over 250 publications and a number of books on wound healing; First President of European Pressure Ulcer Advisory Panel, First Recorder of European Wound Management Association and current President of the European Tissue Repair Society.

Professor of Rehabilitation Medicine (Wound Healing)/ Director Wound Healing Research Unit Cardiff Medicentre Heath Park Cardiff CF14 4UJ

Gary Sibbald, MD, FRCPC, ABIM, DABD, Med

Director of the Wound Healing Clinic at the Women's College Hospital of Toronto; President Elect of World Union of Wound Healing Societies

Women's College Research Institute 790 Bay Street; 7th floor Toronto, ON M5G 1N8 Canada

Sabine Eming MD, PhD

Research aimed at understanding of repair response at molecular level; identification of genes, signals & mechanisms that determine cell function during skin repair; manipulation of healing response to develop regeneration & novel strategies for drug interventions in pathological healing conditions in diabetes mellitus, vascular diseases or aging; interrelation between tissue repair, mechanisms of cancer development & inflammatory skin diseases.

Department of Dermatology Joseph-‐Stelzmann Str. 9 50931 Cologne, Germany

Hilde Beele, MD, PhD

Board Member & Treasurer European Society for Tissue Repair; Head of the Tissue Bank; Dermatologist; Medical Director Ghent Univ. Hospital; research interests in wound bed preparation & healing, graft rejection & survival.

Ghent University Hospital Tissue Bank & Dep’t of Dermatology Ghent, Belgium

Boris Hinz, PhD

Chair of Cell Contractility Group; pathobiology and biophysics of fibroblasts; fibrocontractive diseases, wound healing, tissue remodeling, repair & regeneration; cell biology, bioengineering, cell biophysics & biomechanics, experimental pathology, experimental dermatology, theoretical biology, biomedical imaging; cell contraction & motility; actin isoforms & actin-‐associated proteins; cell-‐cell and cell-‐matrix contacts, mechano-‐transduction

Laboratory of Tissue Repair and Regeneration, Matrix Dynamics Group, Faculty of Dentistry, Fitzgerald Building, University of Toronto, 150 College Street, Toronto, ON M5S 3E2, Canada

Gerrolt Jukema, MD Trauma Surgeon

Working to bring the EWMA further in the field research and evidence based medicine & to set an evidence based standard in wound care.

VU University Medical Centre Head of the Department of Trauma Surgery Amsterdam, The Netherlands




Dimitris Kletsas, PhD

Research interests in mechanisms of cellular senescence & its role in age-‐related disorders (cancer, intervertebral disc degeneration, chronic wounds); growth factor-‐ and stress-‐regulated signaling pathways; extracellular matrix; bioactive compounds from natural products; cell replacement therapy.

Institute of Biology, N.C.S.R. "Demokritos" 153 10 Athens, Greece

David Leaper, MD, ChM, FRCS, FACS

Research interests in surgical infection, sepsis, wound healing; editor and referee for several journals; past president, Surgical Infection Society of Europe & European Wound Mgmt Association; past Hunterian Professor & Zachary Cope lecturer at Royal Coll Surg; published over 10 books, 50 chapters & 250 research & review papers; invited speaker to many societies; chaired & organized national/international committees; speaker/medical advisor for companies in Pharmaceutical Industry.

Emeritus Professor of Surgery, University of Newcastle upon Tyne and Visiting Professor, Department of Wound Healing Cardiff University Wales, UK

Rita Gaspar Videira

In clinical practice since 1991 at S. João Universitary Hospital, in Porto; invited to private medicine for years; has developed a particular interest in wound management.

Hospital S. João, E.P.E. Porto, Portugal

Jose Verdu Soriano

Ph.D. Thesis: Epidemiology, prevention and treatment of pressure ulcers Master in Nursing Sciences (MScN). University of Alicante, 2007

Departamento de Enfermería Comunitaria Campus de Sant Vicent del Raspeig Alicante, Spain

Rytis Rimdeika Head, Dep’t of Plastic & Reconstructive Surgery, Kaunas Medical University Hospital; Hospital Director for Surgery

Department of Surgery Kaunas Medical University Hospital Kaunas, Lithuania

Sylvie Meaume

Co-‐founder, French Journal of Wound Care "Journal des Plaies et Cicatrisations". 1996; Co-‐organizer of the annual French National Meeting '"Conférence des Plaies et Cicatrisations" (more than 3500 participants); Président of the French Society of Wound Healing 2006-‐2009

Geriatric Ward Charles Foix Hospital (Assistance Publique de Paris) Paris, France

Severin Lauchli Staff physician, Dermatological Clinic, University Hospital, Zürich; Responsible for Dermatologic Surgery and Wound Care

Dermatological Clinic University Hospital, Zürich Zürich, Switzerland

Maarten Lubbers

Inflammation; wounds (healing, infection, dressings, tissue engineering); transplantation; infection; sepsis; MOF; antiseptics; evidence; health economics; guidelines.

Academisch Medisch Centrum Amsterdam, Netherlands

Martin Koschnick

Basic principles of wound healing: model for development of granulation tissue in rodents; receptor status in wound healing by FACS; molecular biology in wound healing, role of p53; analysis of mechanism of hypopressure bandage; investigations of role of disinfectants in healing

National Cancer Institute Lisbon, Portugal




Marcus Gurgen

Treatment of all chronic wounds; Established Wound Healing Unit at Sørlandet Sykehus; special interest in diabetic foot ulcers; published articles on the diabetic foot; research in fields of pH in chronic wounds and growth factor treatment; Lectures on chronic wound healing for institutions, medical societies and companies.

Sørlandet Sykehus HF Flekkefjord, Norway

Corrado Durante Chief of the Vulnotherapy Unit, Emergency Dept. Army Military Hospital of Rome

Wound Care Unit Army Military Hospital Piazza Celimontana 50 00184 Roma ITALIA

Carol Dealey

Senior Research Fellow, University Hospital Birmingham NHS Foundation Trust; Research Fellow, School of Health Sciences, University of Birmingham/University Hospital Birmingham NHS Trust; Research Fellow, University Hospital Birmingham NHS Trust; Clinical Nurse Specialist in Tissue Viability, Community Hospitals Division, Southern Birmingham Community Health NHS Trust; Clinical Nurse Specialist in Tissue Viability, Queen Elizabeth Hospital,

EWMA Journal Editor University Hospital Birmingham NHS Foundation Trust Birmingham, UK

Paulo Alves

Member of Portuguese Red Cross; volunteer Nurse since 1999; Trustee EPUAP – European Pressure Ulcer Advisory Panel, since 2007; Member of Scientific Committee of EWMA 2008 Member of APTFeridas – Portuguese Wound Management Association, board since 2008 Member of APNEP – Portuguese Association of Nutrition, since 2008

CHVNG -‐ Centro Hospitalar Vila Nova de Gaia Vila Nova de Gaia, Portugal

Robert Strohal

Past president of Austrian Wound Management Association; current Vice-‐president; European Commission-‐funded concerted action on genetic skin diseases (GENESKIN incl. epidermolysis bullosa); various investigator originated studies with a special focus on new options for the clinical management of MRSA, infection and pain in acute and chronic wounds; 8 national and international scientific awards.

Federal University Teaching Hospital of Feldkirch Department of Dermatology Feldkirch, Austria

Simon Kay, MD

Immediate Past President of BAPRAS; Chairman, BAPRAS' Professional Standards Committee; consultant plastic surgeon; special interest in hand surgery, microsurgery, children’s surgery and breast surgery; Professor of Hand Surgery, University of Leeds; current research includes joint collaboration on nerve repair with Umeä University in Sweden (Hon. Visiting Prof. in Plastic and Hand Surgery).

Univeersity of Leeds Leeds, UK Umea University Plastic and Hand Surgery




Hiroshi Nishikawa, MD

Joined BAPRAS Council in 2008 and will remain on the Council until the end of 2010; BAPRAS representative on Intercollegiate Board in Plastic Surgery from 2008 until 2013; main area of specialty is craniofacial surgery.

The Children's Hospital and Priory Hospital Birmingham, UK

Nicholas Parkhouse

Special interest in aesthetic/cosmetic surgery of the face, breasts, abdomen and trunk, together with non-‐surgical injection and laser treatment for specific problems; special interest in the treatment of scarring disfigurement.

McIndoe Surgical Centre London, UK

Peter Franks, PhD Past President of the European Wound Management Association; Professor of Health Sciences.

Centre for Research and Implementation of Clinical Practice, Thames Valley University London, United Kingdom

Pr. Frank Duteille, MD

Head of the Department of Plastic Reconstructive and Esthetic Surgery

University Hospital Nantes, France

Dieter Mayer, MD Vascular Surgeon, EBSQ-‐VASC, FMH; Senior Consultant, Vascular Surgery; Head of Wound Care

Zurich University Hospital Zurich, Switzerland

Thomas Wild, MD Department of Surgery, University of Vienna; President Elect of Austrian Wound Association

Department of Surgery University of Vienna Vienna, Austria

Mona Baharestani, PhD, ANP, CWOCN, CWS

Associate Professor & Secretary for the Advancement of Wound Care, Center for Nursing Research, East Tennessee State University; Faculty Professor, Oxford University Wound Healing Summer School, UK

Oxford University Wound Healing Summer School, UK

Professor Dr. Med. Matthias Augustin

Professor for Health Economics & Quality of Life Research Group, Department of Dermatology, University Clinics of Hamburg, Germany

Department of Dermatology University Clinics of Hamburg Hamburg, Germany

Walter Ingram, MD

Director of Grady Memorial Hospital Burn Unit; compiled extensive patient database used as fundamental tool in outcomes research; clinical specialties include chemical & electrical burns, surgical critical care, skin grafts, & herpes donor site studies; research interests include patient outcomes post-‐skin replacement, outcomes of diabetic patients with burned feet, & investigation of skin graft donor sites infected with herpes virus.

Grady Memorial Hospital Campus Glenn Memorial Building Room 304 69 Jesse Hill Jr. Drive, SE Atlanta, GA 30303

Jeremy Tamir, MD

Senior Plastic Surgeon; Director of the Wound Care Center at Sheba Medical Center in Israel; founder & chairman of Israeli Wound Healing Society; research on advanced technologies in wound care; Head of the Wound Care and Plastic Surgery Departments.

Sheba Medical Center Israel Wound Care and Plastic Surgery Departments at Halstead Hospital in Kansas, USA.




Chandan K. Sen, PhD

Department of Surgery & Molecular & Cellular Biochemistry; focuses on reactive oxygen species & anti-‐oxidant nutrients with emphasis on tissue injury and repair; Executive Director of OSU Comprehensive Wound Ctr.

The Ohio State University Comprehensive Wound Center.

Stephen M. Milner, MD

Director of Surgery, Johns Hopkins Wound Center; Director, Johns Hopkins Burn Center; specialties include acute burns, burn deformities, facial cancers, necrotizing fasciitis, TEN and complex injuries, scars, acute & reconstr. burn surgery, surgical management of complex wounds, facial reconstruction.

The Johns Hopkins Burn Center at the Johns Hopkins Bayview Medical Center.

Harriet Hopf, MD

Professor, Department of Anesthesiology; research focuses on measuring tissue oxygen & improving wound healing outcomes by increasing oxygen delivery.

University of Utah Department of Anesthesiology Room 3C444 30 N. 1900 East Salt Lake City, UT 84132

Lisa Gould, MD Chief, Plastic Surgery; Professor of Medicine at Univ. of South Florida; Secretary of the Wound Healing Society

James A. Haley Veterans' Hospital Department of Surgery 13000 Bruce B. Downs Blvd. Tampa, FL 33612

Andrew Baird, PhD Professor, Department of Surgery,Division of Trauma, Burns and Wounds

University of California San Diego Department of Surgery Division of Trauma, Burns and Wounds 212 Dickenson Street Mail Stop 8236 San Diego, CA 92103

Stephanie Bernatchez, PhD Advanced Research Specialist at 3M

3M Skin and Wound Care Division 3M Center Bldg, 270-‐3N-‐03 St. Paul, MN 55144

Nicole Gibran, MD

Research emphasizes aberrant healing process including hypertrophic scar formation and chronic non-‐healing wounds seen with diabetes; has over 100 publications in wound repair, response to injury and burns; Director of the UW Burn Center

Harborview Medical Center Department of Surgery 325 Ninth Ave. Box 359796 Seattle, WA 98104

Robert Kirsner, MD, PhD

Director Univ. of Miami Hospital Wound Center; Chief, Dermatology Dep’t, Univ. of Miami Hospital; Co-‐directs Symposium for Advanced Wound Care; serves on planning committee for several meetings; editorial boards for dermatology and wound care journals; board member of Wound Healing Society; past president Association for the Advancement of Wound Care; chairs Medical Advisory Board for National Healing Corp.

University of Miami Department of Dermatology 1600 NW 10th Avenue RMSB 2023A Miami, FL 33136

Lillian Nanney, PhD Investigates cutaneous growth control mechanisms in skin in wound healing settings or whether in benign or neoplastic growth.

Vanderbilt University Medical Center Plastic Surgery, Research Laboratories S-‐221 MCN, 1161 21st Ave. S. Nashville, TN 37232




Laura Parnell, MS, CWS

Founded Precision Consulting; specializes in wound healing & burn research; designs research protocols, develops scientific niche products; international clientele including industry, FDA, & research investigators.

Precision Consulting Clinical Research 6522 Harbor Mist Missouri City, TX 77459

Joyce Stechmiller, PhD, ACNP-‐BC, FAAN

Chronic wound healing; Chair of Adult & Elderly Nursing Department (1998-‐2002); Director of Biobehavioral Research Center (NINR P-‐20); American Society of Enteral & Parenteral Nutrition (Secretary, Nursing Section) & Wound Healing Society Education Cmte.

University of Florida College of Nursing Adult and Elderly Nursing HPNO Box 100187 Gainesville, FL 32610

Paul Takahashi, MD Research interests involve geriatrics and the normal process of aging; wound care.

Bruce Cairns, MD

Director, NC Jaycee Burn Center; critical care, general surgery, trauma, burns, cellular immunology, shock, electrical injury, wound healing, disaster management, telemedicine.

Division of NC Jaycee Burn Center CB #7600 UNC Department of Surgery Chapel Hill, NC 27599

David B. Drake, M.D. Associate Professor of Plastic Surgery, UVA; Co-‐director UVA Hand Fellowship; Medical Director, DeCamp Burn and Wound Center.

Plastic and Reconstructive-‐Uva 101 Hospital Dr #4621 Charlottesville, VA 22908-‐0001

Toshiharu Ishii, MD, PhD

President, Japanese Society for Wound Healing Professor and Chairman, Department of Pathology, School of Medicine.

Toho University School of Medicine Department of Pathology 5-‐21-‐16 Omori-‐nishi Otaku, Tokyo 143-‐8540, Japan

Tal Ellis Vice president, Australian Wound Management Association.

WOUNDHEAL AUSTRALIA PO Box 3454 Norwood, SA 5067, Australia

Robert Mullegger, MD

President, Austrian Wound Association and Scientific Society of Dermatologists, Executive Board, Dep’t of Dermatology at State Hospital.

Austrian Society for Dermatology and Venereologie, Corvinusring 3-‐5 A 2700 Wiener Neustadt, Austria

Thomas Wild, MD President Elect, Austrian Wound Association.

Univ. of Salzburg, Institute of Nursing Sciences, Paracelsus Medical Strubergasse 21, A-‐5020 Salzburg, Austria

Frank Duteille, MD Head of Department of Plastic Reconstructive and Esthetic Surgery, University Hospital.

University Hospital Nantes, France

Dieter Mayer, MD Vascular Surgeon, EBSQ-‐VASC, FMH; Senior Consultant of Vascular Surgery & Head of Wound Care.

University Hospital Zurich Raemistrasse 100 CH-‐8091 Zurich Switzerland

Darrell S. Rigel, MD, MS Clinical Professor of Dermatology

New York University School of Medicine New York, New York

Mark Lebwohl, MD Professor and Chairman, Department of Dermatology.

Mount Sinai School of Medicine New York, New York

Dee Anna Glaser, MD Professor & Vice Chairman, Department of Dermatology.

Saint Louis University 2325 Dougherty Ferry Road, Suite 102 Department of Dermatology




Sheila Fallon Friedlander, MD Clinical Professor of Pediatric and Medicine.

UCSD Division of Pediatric Dermatology Rady Children's Hospital and Health Center 8010 Frost Street, Suite 602 San Diego, CA 92123

Timothy C. Flynn, MD Clinical Professor, Department of Dermatology; Medical Director, Cary Skin Ctr.

Cary Skin Center 200 Wellesley Trade Lane Cary, NC 27519

Boni E. Elewski, M.D. Vice-‐Chair for Clinical Affairs

University of Alabama at Birmingham EFH 414 1530 3RD AVE S BIRMINGHAM AL 35294-‐0009

Roger I. Ceilley, MD Assistant Clinical Professor of Dermatology at Department of Dermatology

Department of Dermatology University of Iowa Hospitals and Clinics 200 Hawkins Drive Iowa City, IA 52242

Roy S. Rogers, III, M.D.

Professor of Dermatology, Mayo Medical School; Consultant in Dermatology, Mayo Clinic; Dean, Mayo School of Health-‐Related Sciences

Mayo Medical Clinic 200 1st Ave E 5B Rochester, MN, 55905

John J. Zone, MD Chairman and Professor of Dermatology.

University Health Care Department of Dermatology 30 North 1900 East, 4A330 School of Med SLC UT 84132

June K. Robinson, MD Section Chief of Dermatology at Dartmouth-‐Hitchcock Medical Center.

Norris Cotton Cancer Center One Medical Center Drive Lebanon, NH 03756

Brett Coldiron, MD, FACP

Clinical Assistant Professor, University of Cincinnati The Skin Cancer Center.

The Skin Cancer Center Cincinnati, OH

Elizabeth Alvarez Connelly, MD

Assistant Professor of Dermatology, Department of Dermatology & Cutaneous Surgery; Assistant Professor, Department of Pediatrics, Division of Pediatric Dermatology.

University of Miami Miller School of Medicine

Joseph L. Jorizzo, MD

Professor, Former and Founding Chair of Dermatology Department at Wake Forest University; Adjunct Professor of Dermatology at the Weill Cornell School of Medicine.

Wake Forest University Department of Dermatology

Wendy E. Roberts, MD, FAAD

Owner Desert Dermatology Skin Institute; Founding Director of Dermatopathology of Loma Linda Division of Dermatology.

Desert Dermatology Skin Institute Rancho Mirage, CA

James Spencer, MD, MS

Director, Spencer Dermatology & Skin Surgery Center; Professor of Clinical Dermatology.

Spencer Dermatology & Skin Surgery Center St. Petersburg, FL

Heidi A. Waldorf, MD Director, Laser and Cosmetic Dermatology Associate Clinical Professor, Department of Dermatology.

Mount Sinai Medical Center New York, NY




Chiming Wei, MD, PhD

Director, Cardiothoracic-‐Renal Nanomedicine Program; Chairman of AANM; Editor-‐in-‐Chief, NANOMEDICINE, and Journal of Cardiothoracic-‐Renal Research; Leader in Global Healthcare Technology Products and Platforms Markets

Leaders in Global Healthcare Technology Products and Platforms Markets

Christopher J. Elias, MD, MPH

President and CEO; Emerging technologies which address global health problems

CEO of Global and National Healthcare Technology Company

Donald W Rucker, MD, MBA, MS

Clinical Assistant Professor of Emergency Medicine; Vice President and Chief Medical Officer. Siemens Medical Solutions

Telemedicine & eHealth

Dr. Adriano Cavalcanti

Medical nanorobotics inventor for practical hardware architecture of nanorobots; Nanorobotics pioneer, Chairman and CEO of CAN Center for Automation in Nanobiotech

Academic Thought Leader in Global Healthcare Technology Products and Platforms Markets

METHODOLOGY Questionnaire

Table 3: Examples of Potential Questions for KOLs

1.) What do you believe are the areas of greatest growth in Advanced Wound Care technologies and therapies over the Mid-‐Term? Do these differ in Europe? Globally?

2.) How do you believe these will be manifested? In Europe? Globally?

3.) What factors would you define as essential to leveraging these new technologies and therapies, particularly over the Mid-‐Term? Do these differ in Europe? Globally?

4.) What do you see as the major macro trends influencing patient and physician acceptance, and reimbursement in the introduction of new Advanced Wound Care technologies or therapies, particularly over the Mid-‐Term? Do these differ in Europe? Globally?

5.) Which of these trends do you believe will have the greatest impact in the Mid-‐Term future? In Europe? Globally?

6.) What do you see as the major macro trends influencing patient and physician acceptance, and reimbursement in the establishment of Advanced Wound Care technologies or



therapies as the Standard of Care, particularly over the Mid-‐Term? Do these differ in Europe? Globally?

7.) Which of these trends do you believe will have the greatest impact in the Mid-‐Term? In Europe? Globally?

8.) Which specific methodologies are you currently promoting/ researching / developing and why? Do these differ in Europe? Globally?

9.) What or who has driven change in Advanced Wound Care technologies and therapies? In Europe? Globally?

10.) Which changes have been the most problematic to achieve? In Europe? Globally?

11.) What issues in regulatory affairs are specific to Advanced Wound Care technologies and therapies? Do these differ in Europe? Globally?

12.) What issues in physician acceptance are specific to the Mid-‐Term market development for Advanced Wound Care technologies? Do these differ in Europe? Globally?

13.) What are the most effective methodologies to use to leverage Advanced Wound Care adjacencies particularly over the Mid-‐Term? In Europe? Globally?

14.) What factors are the most problematic in the development of new Advanced Wound Care technologies? How do you address those factors? In Europe? Globally?

METHODOLOGY Secondary Research Harrison Hayes has an extensive proprietary database of secondary

research that will add exceptional value to obtaining a complete understanding of key methods in leveraging current and future Advanced Wound Care technologies and therapies that are compatible with CLIENT X’s core competencies both in Europe and globally, and with a focus on the Mid-‐Term. Harrison Hayes will provide a thorough ideation of whitespace opportunities within core adjacencies of all Advanced Wound Care Management ecosystems for CLIENT X in order to chart out pathways, timelines and capabilities with newly ideated technologies and therapies, including market outlook, profitability, national and international policy outlook, technology development and utilization, market entry and expansion timing, launch strategy, and expansion method. Subsequent content will provide some interesting findings uncovered from preliminary secondary research.



Syndicated Harrison Hayes has established relationships with a variety of syndicated information providers within the Advanced Wound Care Management technology, medical, and biotechnology fields particularly, but not exclusively, in Europe that are complementary to the core adjacencies of CLIENT X’s current business portfolio.

Publicly Available

Harrison Hayes conducts significant market research within the public domain. We have expertise in identifying key data through journal and trade publications, online subscription databases, Advanced Wound Care Management technology and therapy research data hubs, proprietary data sources and archival research. Internal One of Harrison Hayes’s key assets is the research previously conducted that resides “in-‐house”. Our ability to leverage this data significantly reduces the time constraints associated with providing the required deliverables.

TRENDSPOTTING Trendspotting is a form of trending analysis focused on identifying

unmet needs and emerging opportunities that may provide near-‐term and intermediate-‐term value generation within one or more of the Advanced Wound Care Management technologies and therapies. Trending analysis that is focused on identifying the potential of leveraging current and future Advanced Wound Care Management technologies and therapies that are compatible with CLIENT X’s core competencies particularly, but not exclusively, in Europe, requires primary and secondary research to uncover emerging patterns and useful data. We do not guess trends; we detect, analyze and evaluate them to make evidentially supported projections. For this project, our challenge is to determine the useful data regarding the potential of leveraging current and future Advanced Wound Care technologies and therapies that are compatible with CLIENT X’s core competencies particularly, but not exclusively, in Europe and have significant potential for return on investment. Because CLIENT X’s KOLs have significant insight into the current state of Advanced Wound Care Management technologies and therapies in Europe and globally, they are on the cutting edge of trends and function as valuable resource for understanding real-‐world process evaluation and improvement. Examples of trends that we would like to uncover include:



• Cutting edge approaches and new technologies which identify the potential of leveraging Advanced Wound Care Management technologies and therapies particularly, but not exclusively, in Europe, that are compatible with CLIENT X’s core competencies

• Future trends influencing Advanced Wound Care Management technologies and therapies particularly, but not exclusively, in Europe, that are compatible with CLIENT X’s core competencies

• Changing trends in Advanced Wound Care Management technology and therapy regulatory policy particularly, but not exclusively, in Europe

Trending research is an integral part of a successful research initiative, and Harrison Hayes is confident our trend spotting methods will afford CLIENT X the necessary insight on industry dynamics particularly, but not exclusively, in Europe regarding the identification of current and near-‐ to mid-‐term Advanced Wound Care Management technologies and therapies that are compatible with CLIENT X’s core competencies.



FINAL REPORT Our final deliverable for this project is an Internalized Strategy

Report(“Strataject Report™”). The Strataject Report™ is the culmination of all primary and

secondary research and activities, which have taken place over the duration of the engagement. This report serves as an action plan illustrating the information that will afford CLIENT X the necessary insight on customer industry dynamics regarding identification of unmet needs and emerging opportunities in order to leverage current and mid-‐term Advanced Wound Care Management technologies and therapies particularly, but not exclusively, in Europe that are compatible with CLIENT X’s core competencies. Harrison Hayes will provide a thorough review of the European and Global Advanced Wound Care Management Markets including internal and external drivers and inhibitors, and a review of the business issues, barriers and challenges of the current markets in order to understand those new and emerging opportunities that may provide near-‐term and intermediate-‐term value generation. Harrison Hayes will make recommendation of core competency compatible adjacencies with a particular but not exclusive focus on Europe that can be leveraged for near-‐term and intermediate-‐term value generation. Harrison Hayes will also make recommendation of strategies to leverage patient and physician acceptance, and reimbursement, of current and innovative technologies and therapies in the European and Global Advanced Wound Care Management Market. Harrison Hayes will schedule a time to present and discuss our findings and recommendations to CLIENT X. During this meeting we will discuss in detail our front-‐end research, our findings, and our recommendations for CLIENT X including areas of areas of highest relevance for identification and leveraging of unmet needs and emerging opportunities within the Advanced Wound Care Management technologies and therapies with a particular but not exclusive focus on Europe. Harrison Hayes will also provide a thorough review of market drivers and inhibitors, an analysis of critical success factors, identification and detailed assessment of the opportunities and challenges, and an evaluation of near-‐term and intermediate-‐term value generation including revenue generation and expected return on investment within the European and global Advanced Wound Care Management Market.



PRICING & TIMELINE

Terms: 50% due upon inception of project and 50% due within 30 days of inception. Travel expenses will be billed at cost. CLIENT X will approve all travel expense prior to incurring any costs.

CLIENT X, PLC Harrison Hayes, LLC Signature: _________________________ Signature: _________________________ Name: _____________________________ Name: _____________________________ Title: ______________________________ Title: _______________________________ Date: ______________________________ Date: _______________________________

Activity

Weeks

Fee

25 KIL Interviews

Ideation

Concept/Validation Research

Total Project Duration and Fee

sample advanced wound care market landscape proposal

Health & Medicine